{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:43:28Z","timestamp":1789685008304,"version":"4.0.1"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T00:00:00Z","timestamp":1724889600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jaadinternational.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD International"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.jdin.2024.08.006","type":"journal-article","created":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T06:05:13Z","timestamp":1725257113000},"page":"61-66","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Risk factors that limit use of oral JAK inhibitors in chronic hand eczema: Findings from the Danish Skin Cohort"],"prefix":"10.1016","volume":"17","author":[{"given":"Yuki M.F.","family":"Andersen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Sieborg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea","family":"Nymand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiago","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Chiricozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon Francis","family":"Thomsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob P.","family":"Thyssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8257-1816","authenticated-orcid":false,"given":"Alexander","family":"Egeberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdin.2024.08.006_bib1","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1600-0536.2009.01669.x","article-title":"The epidemiology of hand eczema in the general population-prevalence and main findings","volume":"62","author":"Thyssen","year":"2010","journal-title":"Contact Dermatitis"},{"issue":"6","key":"10.1016\/j.jdin.2024.08.006_bib2","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/cod.13804","article-title":"Prevalence, incidence, and severity of hand eczema in the general population \u2013 a systematic review and meta-analysis","volume":"84","author":"Quaade","year":"2021","journal-title":"Contact Dermatitis"},{"issue":"5","key":"10.1016\/j.jdin.2024.08.006_bib3","first-page":"357","article-title":"Guidelines for diagnosis, prevention, and treatment of hand eczema","volume":"86","author":"Angelova-Fischer","year":"2021","journal-title":"Contact Dermatitis"},{"key":"10.1016\/j.jdin.2024.08.006_bib4","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1034\/j.1600-0846.2001.70402.x","article-title":"Efficacy of corticosteroids in acute experimental irritant contact dermatitis?","volume":"7","author":"Levin","year":"2001","journal-title":"Skin Res Technol"},{"key":"10.1016\/j.jdin.2024.08.006_bib5","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/bjd.21037","article-title":"The pan-JAK inhibitor delgocitinib in a cream formulation demonstrates dose response in chronic hand eczema in a 16-week randomized phase IIb trial","volume":"187","author":"Worm","year":"2022","journal-title":"Br J Dermatol"},{"issue":"9","key":"10.1016\/j.jdin.2024.08.006_bib6","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1111\/jdv.19194","article-title":"Effect of upadacitinib on atopic hand eczema in patients with moderate-to-severe atopic dermatitis: results from two randomized phase 3 trials","volume":"37","author":"Simpson","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jdin.2024.08.006_bib7","series-title":"EMA Confirms Measures to Minimise Risk of Serious Side Effects with Janus Kinase Inhibitors for Chronic Inflammatory Disorders","year":"2023"},{"key":"10.1016\/j.jdin.2024.08.006_bib8","doi-asserted-by":"crossref","DOI":"10.2340\/actadv.v104.18638","article-title":"Risk factors that impact treatment with oral Janus kinase inhibitors among adult patients with atopic dermatitis: a nationwide registry study","volume":"104","author":"Vittrup","year":"2024","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jdin.2024.08.006_bib9","doi-asserted-by":"crossref","DOI":"10.2340\/actadv.v104.19454","article-title":"Real-world experience of abrocitinib treatment in patients with atopic dermatitis and hand eczema: up to 28-week results from the BioDay registry","volume":"104","author":"Kamphuis","year":"2024","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"10.1016\/j.jdin.2024.08.006_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmjopen-2018-028116","article-title":"Prevalence and characteristics of psoriasis in Denmark: findings from the Danish skin cohort","volume":"9","author":"Egeberg","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.jdin.2024.08.006_bib11","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1365-2133.2004.06270.x","article-title":"Construction and validation of a photographic guide for assessing severity of chronic hand dermatitis","volume":"152","author":"Coenraads","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jdin.2024.08.006_bib12","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2147\/CLEP.S91125","article-title":"The Danish National Patient Registry: a review of content, data quality, and research potential","volume":"7","author":"Schmidt","year":"2015","journal-title":"Clin Epidemiol"},{"issue":"3","key":"10.1016\/j.jdin.2024.08.006_bib13","first-page":"798","article-title":"Data resource profile: the Danish national prescription registry","volume":"46","author":"Potteg\u00e5rd","year":"2017","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.jdin.2024.08.006_bib14","series-title":"Danish Society of Obstetrics and Gynaecology's Guideline: Hormonal Contraception and Thromboembolic Disease","author":"Caning","year":"2020"},{"issue":"4","key":"10.1016\/j.jdin.2024.08.006_bib15","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdin.2024.08.006_bib16","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.2147\/TCRM.S292504","article-title":"Drugs for the treatment of chronic hand eczema: successes and key challenges","volume":"16","author":"Dubin","year":"2020","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.jdin.2024.08.006_bib17","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1111\/jdv.19742","article-title":"Inflammatory plasma signature of chronic hand eczema: associations with aetiological and clinical subtypes","volume":"38","author":"Quaade","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10451","key":"10.1016\/j.jdin.2024.08.006_bib18","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0140-6736(24)01027-4","article-title":"Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trials","volume":"404","author":"Bissonnette","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jdin.2024.08.006_bib19","author":"Ritchie"},{"key":"10.1016\/j.jdin.2024.08.006_bib20","author":"Ritchie"},{"key":"10.1016\/j.jdin.2024.08.006_bib21","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1016\/S0140-6736(17)32129-3","article-title":"Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128\u00b79 million children, adolescents, and adults","volume":"390","author":"Abarca-G\u00c3","year":"2017","journal-title":"Lancet"}],"container-title":["JAAD International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666328724001305?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666328724001305?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T19:42:56Z","timestamp":1748547776000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666328724001305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":21,"alternative-id":["S2666328724001305"],"URL":"https:\/\/doi.org\/10.1016\/j.jdin.2024.08.006","relation":{},"ISSN":["2666-3287"],"issn-type":[{"value":"2666-3287","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk factors that limit use of oral JAK inhibitors in chronic hand eczema: Findings from the Danish Skin Cohort","name":"articletitle","label":"Article Title"},{"value":"JAAD International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdin.2024.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the American Academy of Dermatology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}